Novartis Pharmaceuticals Recalls Painkillers and Stomach Medicines

> Novartis Pharmaceuticals Recalls Painkillers and Stomach Medicines (Alberta Times) The Federal Food and Drug Administration (FDA) warned on the 9th that Novartis Pharmaceuticals (Novarti...

Novartis Pharmaceuticals Recalls Painkillers and Stomach Medicines (Alberta Times) The federal Food and Drug Administration (FDA) warned on the 9th that due to a manufacturing error at a Novartis plant in Lincoln, Nebraska, powerful painkillers may have been mixed into bottles of common painkillers and stomach medicines purchased without a prescription, such as Excedrin, Gas-X, etc. Novartis Pharmaceuticals has issued a comprehensive recall of painkillers and stomach medicines produced at the factory on the 8th. Novartis received complaints that broken and broken tablets were found, as well as inconsistent drug packaging. The company said that consumers should stop using these medicines and contact the company for a refund. On the 8th, Novartis announced the recall of the headache drug Excedrin and the caffeine pill NoDoz, which expired on December 20, 2014, as well as the painkiller Bufferin and stomach medicine G that expired on December 20, 2013 and earlier. as - FDA officials said on the 9th that painkillers produced by Novartis Pharmaceuticals may be mixed with powerful painkillers also manufactured in the state's factories, including Endo Pharmaceuticals' opioid drugs Percocet, Endocet, Opana and Zydone. Endo Pharmaceuticals said there are no confirmed reports of mixed pills making consumers sick. FDA official Cox said the agency is not recalling the painkillers because many patients need them and the chances of getting the wrong ones are low, so patients don't need to be overly nervous. Cox said the agency is currently inspecting the plant and found a manufacturing error that could have caused the pills to get stuck in the machine and get into the packaging of other drugs. Cox said the agency is concerned about the shortage of painkillers at the Endo plant in the coming weeks because Novartis stopped production at the plant last month. The extent of the shortage will depend on how quickly factories can put safety mechanisms in place to prevent similar situations from happening in the future, the FDA said in a statement.